ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - c - 1 esterase inhibitor human 500 units - lyophilized powder for solution for injection - c1-inhibitor - treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (hae). routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (hae), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

ישראל - עברית - Ministry of Health

"פייזר פרמצבטיקה בע""מ" - כלל האוכלוסיה - משאף ויחידת שחרור אינסולין

ישראל - עברית - Ministry of Health

adoni medical - כלל האוכלוסיה - משאף גבישי מלח

ישראל - עברית - Ministry of Health

tree of life pharma ltd. - כלל האוכלוסיה - משאף לאף

ישראל - עברית - Ministry of Health

טעם טבע אלטמן שותפות כללית - כלל האוכלוסיה - להקלה של נשימה במצבים של אסטמה, אלרגיות ובעיות מערכת הנשימה. לשיפור איכות השינה

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - salbutamol as sulfate 100 mcg/dose - inhaler, cfc free - salbutamol - relief of bronchospasm in bronchial asthma of all types, chronic bronchitis and emphysema.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - טבליות בשחרור מבוקר - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 150 mg; carbidopa 37.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

ישראל - עברית - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.